compounding glp-1 enforcement news FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads FDA Crackdown on Compounded GLP-1

Youve been dieting as long as you can remember and nothing happens

Taking a closer look at Primes GLP-1 Year-2 cost-of-care findings David Lassen, vice president of pharmacy clinical services, and Marci Chodroff, vice president and medical director at Prime Therapeutics, share more about the latest GLP-1 insights from ongoing research Last week, Prime Therapeutics (Prime) released the latest data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, which showed individuals who newly started the drugs for weight loss experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity

Were withholding it because the studies that would answer these questions havent been done yet

Asthma and bronchospasm